Jiangsu Jibeier Pharmaceutical Co Ltd (688566) - Net Assets
Based on the latest financial reports, Jiangsu Jibeier Pharmaceutical Co Ltd (688566) has net assets worth CN¥2.50 Billion CNY (≈ $365.83 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.72 Billion ≈ $398.43 Million USD) and total liabilities (CN¥222.75 Million ≈ $32.60 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 688566 goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥2.50 Billion |
| % of Total Assets | 91.82% |
| Annual Growth Rate | 23.63% |
| 5-Year Change | 52.31% |
| 10-Year Change | N/A |
| Growth Volatility | 71.93 |
Jiangsu Jibeier Pharmaceutical Co Ltd - Net Assets Trend (2016–2025)
This chart illustrates how Jiangsu Jibeier Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. See Jiangsu Jibeier Pharmaceutical Co Ltd liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Jiangsu Jibeier Pharmaceutical Co Ltd (2016–2025)
The table below shows the annual net assets of Jiangsu Jibeier Pharmaceutical Co Ltd from 2016 to 2025. For live valuation and market cap data, see Jiangsu Jibeier Pharmaceutical Co Ltd (688566) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥2.45 Billion ≈ $358.46 Million |
+8.69% |
| 2024-12-31 | CN¥2.25 Billion ≈ $329.81 Million |
+17.98% |
| 2023-12-31 | CN¥1.91 Billion ≈ $279.55 Million |
+12.75% |
| 2022-12-31 | CN¥1.69 Billion ≈ $247.93 Million |
+5.35% |
| 2021-12-31 | CN¥1.61 Billion ≈ $235.34 Million |
+2.03% |
| 2020-12-31 | CN¥1.58 Billion ≈ $230.67 Million |
+235.06% |
| 2019-12-31 | CN¥470.46 Million ≈ $68.84 Million |
+31.53% |
| 2018-12-31 | CN¥357.68 Million ≈ $52.34 Million |
-18.85% |
| 2017-12-31 | CN¥440.76 Million ≈ $64.50 Million |
+21.37% |
| 2016-12-31 | CN¥363.15 Million ≈ $53.14 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Jiangsu Jibeier Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 404.9% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥807.96 Million | 33.25% |
| Other Components | CN¥1.62 Billion | 66.75% |
| Total Equity | CN¥2.43 Billion | 100.00% |
Jiangsu Jibeier Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Jiangsu Jibeier Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Beijing Fengshangshiji Culture Medi
SHE:300860
|
$730.77 Million |
|
Energy Vault Holdings Inc
NYSE:NRGV
|
$730.81 Million |
|
Siantar Top Tbk
JK:STTP
|
$731.15 Million |
|
Vishay Precision Group Inc
NYSE:VPG
|
$731.28 Million |
|
Bangkok Chain Hospital Public Company Limited
BK:BCH
|
$730.64 Million |
|
Yuanli Chemical Group Co Ltd
SHG:603217
|
$730.49 Million |
|
GHT Co Ltd Class A
SHE:300711
|
$730.45 Million |
|
Anbio Biotechnology Class A Ordinary Shares
NASDAQ:NNNN
|
$730.35 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Jiangsu Jibeier Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,248,637,420 to 2,430,060,871, a change of 181,423,451 (8.1%).
- Net income of 258,668,188 contributed positively to equity growth.
- Dividend payments of 103,704,050 reduced retained earnings.
- Other comprehensive income decreased equity by 99,715,432.
- Other factors increased equity by 126,174,744.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥258.67 Million | +10.64% |
| Dividends Paid | CN¥103.70 Million | -4.27% |
| Other Comprehensive Income | CN¥-99.72 Million | -4.1% |
| Other Changes | CN¥126.17 Million | +5.19% |
| Total Change | CN¥- | 8.07% |
Book Value vs Market Value Analysis
This analysis compares Jiangsu Jibeier Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.05x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 9.82x to 2.05x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | CN¥2.55 | CN¥25.04 | x |
| 2017-12-31 | CN¥3.08 | CN¥25.04 | x |
| 2018-12-31 | CN¥2.51 | CN¥25.04 | x |
| 2019-12-31 | CN¥3.33 | CN¥25.04 | x |
| 2020-12-31 | CN¥9.32 | CN¥25.04 | x |
| 2021-12-31 | CN¥8.50 | CN¥25.04 | x |
| 2022-12-31 | CN¥9.06 | CN¥25.04 | x |
| 2023-12-31 | CN¥10.17 | CN¥25.04 | x |
| 2024-12-31 | CN¥11.59 | CN¥25.04 | x |
| 2025-12-31 | CN¥12.21 | CN¥25.04 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Jiangsu Jibeier Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 10.64%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 26.81%
- • Asset Turnover: 0.36x
- • Equity Multiplier: 1.12x
- Recent ROE (10.64%) is below the historical average (14.78%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 21.57% | 17.31% | 0.92x | 1.35x | CN¥41.27 Million |
| 2017 | 17.85% | 17.14% | 0.86x | 1.22x | CN¥34.10 Million |
| 2018 | 27.54% | 19.92% | 1.01x | 1.36x | CN¥61.53 Million |
| 2019 | 24.35% | 20.81% | 0.91x | 1.28x | CN¥66.54 Million |
| 2020 | 8.26% | 22.92% | 0.32x | 1.11x | CN¥-27.23 Million |
| 2021 | 7.17% | 22.54% | 0.28x | 1.14x | CN¥-45.30 Million |
| 2022 | 9.16% | 23.62% | 0.33x | 1.16x | CN¥-14.18 Million |
| 2023 | 11.50% | 25.45% | 0.39x | 1.16x | CN¥28.60 Million |
| 2024 | 9.75% | 24.46% | 0.35x | 1.12x | CN¥-5.54 Million |
| 2025 | 10.64% | 26.81% | 0.36x | 1.12x | CN¥15.66 Million |
Industry Comparison
This section compares Jiangsu Jibeier Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $4,041,443,343
- Average return on equity (ROE) among peers: 10.73%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Jiangsu Jibeier Pharmaceutical Co Ltd (688566) | CN¥2.50 Billion | 21.57% | 0.09x | $730.74 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $971.04 Million | 5.41% | 3.98x | $565.97 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.33 Billion | 6.10% | 1.68x | $359.03 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $8.39 Billion | 22.09% | 0.19x | $4.30 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $3.01 Billion | 11.93% | 0.53x | $2.52 Billion |
| Wedge Industrial Co Ltd (000534) | $1.15 Billion | 11.42% | 1.59x | $2.41 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $1.42 Billion | 23.64% | 1.01x | $12.64 Billion |
| Hainan Haiyao Co Ltd (000566) | $445.29 Million | 14.73% | 0.90x | $715.72 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $347.80 Million | 3.58% | 0.72x | $319.94 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $905.53 Million | 2.15% | 1.95x | $916.75 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $22.44 Billion | 6.25% | 0.15x | $3.00 Billion |
About Jiangsu Jibeier Pharmaceutical Co Ltd
Jiangsu Jibeier Pharmaceutical Co., Ltd., a pharmaceutical company, engages in the drug research and development and production in China. The company's products cover multiple therapeutic areas such as increasing white blood cells, fighting hypertension, enhancing immunity, treating joint diseases, fighting eye infections, treating bronchitis, protecting liver function, etc. It is also developing… Read more